OLANZAPINE | N021253 | CHEPLAPHARM REGISTRATION GMBH
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Centre for Addiction and Mental Health | 64 | 2019-10-22 → 2026-07-30 | |
| Phase 1 | Active | National Cancer Institute (NCI) | 11 | 2020-07-07 → 2028-07-30 | |
| Phase 2 | Recruiting | The Hospital for Sick Children | 200 | 2017-08-10 → 2026-04 | |
| Phase 1 | Recruiting | University of Arizona | 24 | 2017-11-20 → 2026-02-10 | |
| Phase 4 | Completed | Dost Ongur | 35 | 2017-11-17 → 2019-11-08 | |
| Phase 3 | Completed | Department of Medical Services Ministry of Public Health of Thailand | 90 | 2020-03-01 → 2021-09-30 | |
| Phase 2 | Completed | Herzog Hospital | 18 | 2009-01 → 2013-02 | |
| Phase 4 | Completed | Hamilton Health Sciences Corporation | 34 | 2000-06 → 2006-03 | |
| Phase 1 | Completed | Calo Psychiatric Center | 111 | 2008-01 → 2008-12 | |
| Phase 3 | Completed | Ottawa Hospital Research Institute | 221 | 2016-12 → 2019-12-23 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$37.62
Highest Price
$47.19
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 00002-7597-01ZYPREXA INTRAMUSCULAR 10MG F/INJ | $47.19 | FSS | H2-Pharma, LLC | 10/01/2026 |
| 00002-7597-01ZYPREXA INTRAMUSCULAR 10MG F/INJ | $37.62 | Big4 | H2-Pharma, LLC | 10/01/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
24 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Feb 3, 2026 | SUPPL -67 | View Letter (PDF) |
| Feb 7, 2025 | SUPPL -66 | View Letter (PDF) |
| Apr 24, 2020 | SUPPL -61 | View Letter (PDF) |
| Apr 22, 2020 | SUPPL -62 | View Letter (PDF) |
| Oct 23, 2019 | SUPPL -60 | View Letter (PDF) |
| Mar 29, 2018 | SUPPL -59 | View Letter (PDF) |
| Mar 2, 2017 | SUPPL -57 | View Letter (PDF) |
| Mar 2, 2017 | SUPPL -58 | View Letter (PDF) |
| Oct 14, 2016 | SUPPL -56 | View Letter (PDF) |
| Dec 23, 2014 | SUPPL -48 | View Letter (PDF) |
| Dec 6, 2010 | SUPPL -45 | View Letter (PDF) |
| Jun 3, 2010 | SUPPL -39 | View Letter (PDF) |
| Jun 3, 2010 | SUPPL -43 | View Letter (PDF) |
| Feb 1, 2010 | SUPPL -37 | View Letter (PDF) |
| Nov 19, 2009 | SUPPL -36 | View Letter (PDF) |
| Aug 19, 2008 | SUPPL -33 | View Letter (PDF) |
| Jul 10, 2007 | SUPPL -26 | View Letter (PDF) |
| Dec 28, 2006 | SUPPL -21 | View Letter (PDF) |
| Sep 18, 2006 | SUPPL -6 | View Letter (PDF) |
| Mar 1, 2006 | SUPPL -16 | View Letter (PDF) |
| Feb 22, 2006 | SUPPL -4 | View Letter (PDF) |
| Feb 22, 2006 | SUPPL -12 | View Letter (PDF) |
| Sep 15, 2005 | SUPPL -15 | View Letter (PDF) |
| Apr 7, 2004 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.